Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Chronic Hepatitis B Virus Infection Clinical Trial

Official title:
A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and Pegylated Interferon Alpha (PEG-IFNα) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

Status Active, not recruiting

Clinical Trial Summary

This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with different dose levels of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05970289
Study type	Interventional
Source	Brii Biosciences Limited
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	August 22, 2023
Completion date	February 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01708889` - Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction	Phase 1
Recruiting	`NCT05494528` - Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy	N/A
Recruiting	`NCT05382351` - Antiviral Therapy for Patients With Chronic Hepatitis B Infection	Phase 2
Not yet recruiting	`NCT06159062` - A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection	Phase 1
Terminated	`NCT04971512` - A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.	Phase 1